Loading patent…
AssigneeAir Liquide Sante (International)
InventorsMarc LEMAIRE, Jacques Abraini
Estimating the term…
The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.
An inhalable medical gaseous composition for administration to humans that is suitable for treating amphetamine addiction, said composition comprising from 15% to 80% by volume of gaseous argon with the remainder being oxygen or nitrogen or mixtures thereof.
An inhalable medical gaseous composition comprising from 15% to 80% by volume of gaseous argon and at least on additional gaseous compound selected from xenon, krypton and nitrous oxide.
A method for treating neurointoxication in a human, the method comprising administering by inhalation to a human a therapeutically effective amount of an inhalable medicinal product that comprises from between 15% and 80% by volume of gaseous argon.
Dependencies are inferred from the claim text.